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Twenty tropical diseases have been listed by the World Health Organization (WHO) as Neglected
Tropical Diseases (NTDs). These tropical diseases are called “neglected” for three primary reasons: 1)
These diseases are widespread worldwide among the economically weaker (neglected?) section of the
society; 2) Although the total number of mortality, morbidity, disability, and health disparity caused
annually by the NTDs is more than that attributed by the so-called elite diseases like cancer, diabetes,
human immunodeﬁciency virus/acquired immunodeﬁciency syndrome (HIV/AIDS), cardio- or
neurological diseases but NTD patients do not receive comparable attention or treatment
opportunities either from the governments or healthcare professionals or non-governmental
organizations (NGOs); 3) The scope of drug development research in this ﬁeld is minimal due
to insufﬁcient (negligible) funding, and pharma giants are not interested in developing effective
drugs for NTDs on time, due to insigniﬁcant proﬁt. It is highly challenging to develop new and novel
drugs to combat these tropical diseases to upthrust the lifespan and lifestyle of the socioeconomically
deprived people affected by NTDs (Figure 1). The major goal of this research topic is to shed light on
the global scenario (current status of the ailments, treatment options, and recent drug development
efforts) of three major NTDs, viz. Chagas disease (American trypanosomiasis), Human African
trypanosomiasis (HAT), and Leishmaniasis. This research topic contains three reviews and seven
research articles.
Mother Nature can be an excellent source of leishmanicidal compounds. An in-depth review
summarizing the leishmanicidal activity of various crude extracts and isolated compounds against
promastigote and amastigote (intracellular and axenic) forms has been published (Gervazoni et al.).
The leishmanicidal activity of different classes of compounds such as alkaloids, terpenoids,
ﬂavonoids, coumarins, quinones, and their respective biosynthetic pathways, published between
2000–2020, has been counted in. Mechanisms of action of various natural compounds (if known)
have also been discussed in this review.
Bijlmakers speciﬁed the limitation of effective drugs for treating trypanocidal and leishmanicidal
infections. In treating trypanosomatid diseases, the author reviewed the protozoal ubiquitinproteasome system as potential therapeutic targets (primarily UBA1 and ubiquitin-like
enzymes). This review discussed the mechanisms of action of a series of ubiquitination inhibitors.
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sequence consisting of mesylation-Friedel-Crafts acylation-DielsAlder reaction-heterocyclization-demesylation was used to synthesize
the guaiacol-bearing tetrahydrophthalazinone derivatives. Therefore,
the phenolic-OH group was explored to synthesize a series of
corresponding diaryl/heteroaryl ether derivatives. The compounds
showed selectivity while compared to MRC-5 cell lines.
Cu(II)-mediated 1,3-dipolar alkyne-azide cycloaddition
strategy was followed to synthesize 16 triazolyl proline
derivatives (Fargnoli et al.). The authors evaluated the endproducts as L-proline transport inhibitors against Trypanosoma
cruzi epimastigotes, and cytotoxicity was measured in VERO cell
lines. This study identiﬁed the 1, 2, 3-triazole as an appropriate
linker for the transport inhibitors and effectively validated
L-proline uptake blockers as trypanocidal agents.
Amphotericin B is a natural polyene compound that belongs to
the WHO’s list of essential medicines. Gedda et al. developed a
nanostructure-based method for targeted delivery of Amphotericin
B. The f-Comp-AmB nanocomposite demonstrated multi-fold
better leishmanicidal activity than two previously reported
nanocomposites of the drug and the drug itself against the
intracellular amastigotes of L. donovani in the J774A.1 cell lines.
In addition, the f-Comp-AmB composite showed lower
cytotoxicity than two other nanocomposites of Amphotericin B.
Environmental protection is one of the signiﬁcant criteria in
modern drug discovery research. Rock et al. reported an
ultrasound-assisted on-water synthesis of benzopyrazines
without using any catalyst/support/additive. A series of eleven
benzopyrazines were synthesized and evaluated in vitro. One
benzopyrazine demonstrated comparable trypanocidal and
leishmanicidal activities with commercial drugs (Rock et al.).
Two other benzopyrazines showed moderate leishmanicidal
activity against L. mexicana (M378) strain. The authors
hypothesized the inhibition of four enzymes as biomolecular
targets and validated the hypothesis by in silico and in vitro
evaluations.
In a timely manner, this research topic presents a concise
account of the current status and drug discovery approaches
related to three neglected tropical diseases: Chagas disease, HAT,
and leishmaniasis. Appropriate actions should be taken to protect
millions of people worldwide who are struggling with a fatality,
disability, disruption of social life, and seclusion.

FIGURE 1 | Global scenario of three neglected tropical diseases:
Chagas disease (American trypanosomiasis), Human African trypanosomiasis
(HAT), and Leishmaniasis.

Brindha et al. reviewed the mechanisms of action of the targetbased trypanocidal and leishmanicidal pharmaceutics and
druglike molecules. A few signiﬁcant biomolecular targets such
as trypanothione reductase, cathepsin L-cysteine protease (cruzain),
CYP51 (sterol 14-ademethylase), kinetoplastid proteasome, heme
peroxidation, have been discussed in detail. This review also
includes a discussion on nano-formulation of the therapeutics.
The Leishmania infantum arginase (LiARG) was considered as
a drug target for antileishmanial evaluation, and a series of
chalcone derivatives were screened (Garcia et al.). In this
study, three chalcone derivatives were identiﬁed as LiARG
inhibitors. Moreover, three chalcone derivatives demonstrated
activity against the promastigote and intracellular amastigote
forms of Leishmania infantum. The authors proposed the
presence of a nitro group at the para-position on chalcone “B”
ring as an essential factor to induce leishmanicidal activity.
The heat shock protein 90 (Hsp90) inhibitors such as 17dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)
could be a therapeutic option for treating cutaneous leishmaniasis.
Cruz et al. reported developing 17-DMAG-containing nanoparticles
using poly(lactic-co-glycolic acid) via a double emulsion
procedure. The nanoparticles were internalized by macrophages
and accumulated in the cell cytoplasm. The authors evaluated the
release kinetics of 17-DMAG from the nanoparticle.
Chemical modiﬁcation of medicinally privileged molecules
targeting more potent and/or selective molecules is ongoing in
drug discovery research. Sijm et al. successfully conducted
chemical modiﬁcation of one of their previously reported
trypanocidal molecules with particular attention to reduce the
cLogP values of their newly synthesized molecules with similar
potency. It is expected that the newly synthesized N-substituted
dihydropyrazolone derivatives should demonstrate better drug
metabolism and pharmacokinetics (DMPK) properties (Sijm et al.).
The authors have studied the qualitative structure-activity
relationship (SAR) by diversifying the substituent on the nitrogen
atom adjacent to the carbonyl group in the dihydropyrazolone core.
The small molecule TbrPDEB1 inhibitors can play an important
role against the protozoan T. brucei. Thus, a series of small molecule
tetrahydrophthalazinone derivatives have been designed through
structure-guided virtual screening (Heuvel et al.). A multi-step
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